Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, announced that it received the best-in-class Public Offering Award presented at the 20th annual SEBIO Investor and Partnering Forum.
“We are honored to be recognized for our successful initial public offering earlier this year, raising over $53 million in gross proceeds,” stated Neal Fowler, Liquidia’s Chief Executive Officer. “This milestone reflects the hard work of our employees and the commitment and belief of our investors. On behalf of the Liquidia team, I want to thank SEBIO for this honor, as well as congratulate all other award recipients.”
Annually, SEBIO recognizes best-in-class deals by the region’s biomedical companies in five categories: Public Offering, Strategic Acquisition, Strategic Investment, Venture Funding and Initial Venture Funding. The winners of the 2018 SEBIO awards were announced and recognized at the annual SEBIO Investor and Partnering Forum held in Atlanta, GA.
More than 300 biotech and medtech investors, corporate executives, university representatives and entrepreneurs attend the two-day SEBIO event. The conference connects emerging companies with potential investors and corporate partners. To date, more than 220 later stage and 180 early stage companies that participated in previous SEBIO Investor and Partnering Forums have raised more than $3.5 billion in public and private funding.
About Liquidia Technologies
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology. For more information visit our website at www.liquidia.com. Contact:Jennifer AlmondDirector, Investor Relations & Corporate Communications 919.328.4389 firstname.lastname@example.org